We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships

Yashoda Medicity, GE Healthcare strengthen partnership to expand AI-powered critical care

Discussions focus on integrating ECG diagnostics into AI-enabled E-ICU Command Centre and expanding technology-driven healthcare access across underserved regions

India’s bioeconomy grew 20-fold in last 12 years: Dr Jitendra Singh

From a $10 billion bioeconomy to over $190 billion, indigenous CAR-T therapy, and a booming startup ecosystem highlight 12 years of transformation in India’s science and technology landscape

FDA clears Dexcom’s Stelo as first OTC Continuous Glucose Monitor for kids

Expanded indication makes Stelo the first FDA-cleared OTC CGM for children aged two years and older with diabetes or prediabetes

Orionis expands Novartis partnership in potential $1.4 billion molecular glue drug feal

Lilly’s Jaypirca cuts risk of disease progression or death by 45% in landmark trial

The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor

OM Pharma to unveil major real-world evidence breakthrough on Broncho-Vaxom at EAACI

The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months

Siemens Healthineers begins manufacturing of Atellica chemistry reagents in India

Production at Vadodara facility strengthens Make in India initiative, enhances access to diagnostic testing, and supports preventive healthcare across the country

Philips partners with Bajaj to build digitally connected healthcare network in India

Collaboration to deploy Philips’ IntelliBridge Enterprise platform across Bajaj Integrated Health System network, enabling seamless patient data flow and integrated care delivery.

Mabion reactivates MabionCD20 through rare disease collaboration with Oddifact

MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies